Copper Histidinate: FDA-Approved Treatment for Menkes Disease
- The FDA has approved copper histidinate injection (Zycubo [previously CUTX-101]; Sentynl Therapeutics), the first and only treatment for pediatric patients with Menkes disease, according to news releases from...
- Even though treatment-emergent adverse effects (TEAEs) were reported in 61 subjects (92.4%), none were considered related to the study treatment.
- Pharmacists can play a key role in counseling parents and caregivers of children with Menkes disease who begin treatment with copper histidinate.
“`html
The FDA has approved copper histidinate injection (Zycubo [previously CUTX-101]; Sentynl Therapeutics), the first and only treatment for pediatric patients with Menkes disease, according to news releases from the FDA and Sentynl therapeutics.1,2
Pharmacists can play a key role in counseling parents and caregivers of children with Menkes disease who begin treatment with copper histidinate. Patients should be consistently monitored by pharmacists and other members of the care team to ensure that copper histidinate is being administered correctly and without adverse effects. If teaes are observed, a pharmacist can ensure referral to a specialty care team or hospital setting for prompt treatment. They can also recommend over-the-counter pain relief or prescribe treatments for more specific ailments related to menkes disease.
“This milestone represents the culmination of decades of research into better understanding and ultimately finding an effective treatment for Menkes disease,” Stephen Kaler, MD, a clinical genetics and genomics specialist at the Columbia University Medical Centre, saeid in a news release from Sentynl Therapeutics. “Increased awareness of Menkes disease and rapid testing upon suspicion are critical, as beginning copper histidinate therapy in affected neonates has been shown to reduce symptoms and prolong life.”2
REFERENCES
1. FDA approves first treatment for children with Menkes disease. News Release. FDA. Released January 12, 2026. Accessed January 13, 2026.Menkes Disease: Research & Treatment Updates (as of January 14, 2026)
Table of Contents
The provided text references research related to Menkes disease, a rare X-linked recessive genetic disorder affecting copper metabolism. here’s a breakdown of verified information, updated as of January 14, 2026:
Understanding Menkes Disease
Menkes disease, also known as kinky hair syndrome, is characterized by impaired absorption of copper, leading to a deficiency in several copper-dependent enzymes. This deficiency affects brain advancement, connective tissue formation, and other vital processes. The National Center for biotechnology Information (NCBI) provides a comprehensive overview of the disease, its genetic basis, and clinical manifestations.
Copper Histidinate Treatment Research
The text cites a 2022 Pediatrics publication by Kaler et al. regarding copper histidinate treatment for Menkes disease.
* Verification: The study, “Copper-Histidinate Treatment for Menkes Disease”, was presented as an abstract at a Pediatrics meeting in February 2022. It details the use of copper histidinate, a copper salt, as a potential treatment to improve copper levels and perhaps mitigate some of the disease’s effects.
* Current Status (as of January 14, 2026): As of this date, copper histidinate remains an investigational treatment for Menkes disease. The Menkes disease Foundation reports ongoing research and clinical trials exploring the efficacy and long-term effects of copper histidinate therapy. While early results are promising, it is indeed not yet a standard of care. Further research is needed to determine optimal dosage,timing of treatment,and long-term outcomes.
* FDA status: As of January 14, 2026, copper histidinate is not FDA-approved for the treatment of Menkes disease. The U.S. Food and Drug Administration (FDA) website provides information on approved drugs and ongoing clinical trials.
* Kaler SG: A researcher involved in the copper histidinate treatment study. Further information on Dr. Kaler’s research can be found through PubMed.
* American Academy of Pediatrics (AAP): The publisher of Pediatrics, the journal where the research was presented. The AAP website provides resources for pediatricians and information on child health.
* Menkes Disease foundation: A patient advocacy institution dedicated to supporting families affected by Menkes disease and funding research.
Disclaimer: This information is based on publicly available data as of January 14, 2026, and should not be considered medical advice. consult with a qualified healthcare professional for diagnosis and treatment of Menkes disease.
Table of Contents
The provided text references research related to Menkes disease, a rare X-linked recessive genetic disorder affecting copper metabolism. here’s a breakdown of verified information, updated as of January 14, 2026:
Understanding Menkes Disease
Menkes disease, also known as kinky hair syndrome, is characterized by impaired absorption of copper, leading to a deficiency in several copper-dependent enzymes. This deficiency affects brain advancement, connective tissue formation, and other vital processes. The National Center for biotechnology Information (NCBI) provides a comprehensive overview of the disease, its genetic basis, and clinical manifestations.
Copper Histidinate Treatment Research
The text cites a 2022 Pediatrics publication by Kaler et al. regarding copper histidinate treatment for Menkes disease.
* Verification: The study, “Copper-Histidinate Treatment for Menkes Disease”, was presented as an abstract at a Pediatrics meeting in February 2022. It details the use of copper histidinate, a copper salt, as a potential treatment to improve copper levels and perhaps mitigate some of the disease’s effects.
* Current Status (as of January 14, 2026): As of this date, copper histidinate remains an investigational treatment for Menkes disease. The Menkes disease Foundation reports ongoing research and clinical trials exploring the efficacy and long-term effects of copper histidinate therapy. While early results are promising, it is indeed not yet a standard of care. Further research is needed to determine optimal dosage,timing of treatment,and long-term outcomes.
* FDA status: As of January 14, 2026, copper histidinate is not FDA-approved for the treatment of Menkes disease. The U.S. Food and Drug Administration (FDA) website provides information on approved drugs and ongoing clinical trials.
* Kaler SG: A researcher involved in the copper histidinate treatment study. Further information on Dr. Kaler’s research can be found through PubMed.
* American Academy of Pediatrics (AAP): The publisher of Pediatrics, the journal where the research was presented. The AAP website provides resources for pediatricians and information on child health.
* Menkes Disease foundation: A patient advocacy institution dedicated to supporting families affected by Menkes disease and funding research.
Disclaimer: This information is based on publicly available data as of January 14, 2026, and should not be considered medical advice. consult with a qualified healthcare professional for diagnosis and treatment of Menkes disease.